Evidence map›Paper›PMID 41968244›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

CRISPR-Cas9 and Microhomology-Mediated End-Joining for Biosynthetic Pathway Reconstruction in Aspergillus fumigatus.

Yaojie Guo, Daniel H Scharf

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yaojie GuoZhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou, China.
Daniel H ScharfDepartment of Microbiology, School of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou, People's Republic of China. dhscharf@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have recently engineered Aspergillus fumigatus using an AMA1-based episomal expression CRISPR vector and a microhomology-mediated end-joining repair system. We adopted A. fumigatus as a heterologous expression host to investigate the biosynthetic pathways of epipolythiodioxopiperazine-type compounds. In the present chapter, we describe the assembly of the CRISPR-Cas9 vector and microhomology template plasmid, their transformation into A. fumigatus, and metabolite detection.

Indexed as

Aspergillus fumigatusBiosynthetic PathwaysCRISPR-Cas SystemsGenetic VectorsGliotoxinPiperazinesPlasmidsepipolythiodiketopiperazineGliotoxinPiperazinesAspergillus fumigatusChaetomium cochliodesCRISPR-Cas9EpipolythiodioxopiperazineFungal biosynthesisGliotoxinMicrohomology-mediated end-joiningPathway reconstruction

Identifiers

PMID41968244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.